Methylphenidate
- Generic Name
- Methylphenidate
- Brand Names
- Adhansia, Aptensio, Biphentin, Concerta, Cotempla, Daytrana, Foquest, Jornay, Metadate, Methylin, Quillichew, Quillivant, Relexxii, Ritalin
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19NO2
- CAS Number
- 113-45-1
- Unique Ingredient Identifier
- 207ZZ9QZ49
- Background
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve ...
- Indication
Methylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy
- Associated Therapies
- -
Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00302393
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults
- Conditions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00301639
- Locations
- 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States
Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 39
- Registration Number
- NCT00273741
- Locations
- 🇫🇷
Unité de Soins Palliatifs, Saint-Etienne, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇫🇷EMSP, Hôpitaux du Léman, Thonon-les-bains, France
Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-06-14
- Lead Sponsor
- Alza Corporation, DE, USA
- Registration Number
- NCT00269815
A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children
- Conditions
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Alza Corporation, DE, USA
- Registration Number
- NCT00269789
A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Alza Corporation, DE, USA
- Registration Number
- NCT00269802
Treatment of Patients With Alcoholism and Attention Deficit Disorder
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 100
- Registration Number
- NCT00261872
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Placebo-Controlled Comparison of Two Different Brands of Modified-Release Oral Dosage Forms Regarding Safety and Efficacy in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14
- Conditions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 130
- Registration Number
- NCT00254878
- Locations
- 🇩🇪
Novartis Investigational Site, Freiburg, Germany
Apathy Associated With Alzheimer's Disease
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 40
- Registration Number
- NCT00254033
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride) in the Treatment of Adolescents With Attention Deficit Hyperactivity Disorder
- Conditions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2010-04-28
- Target Recruit Count
- 220
- Registration Number
- NCT00249353
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.